Frequently Asked Questions about the GFN
The rapid development and use of safer nicotine products raises a number of challenging scientific questions about their safety, who uses them and why, and the impact on smoking. These products also raise challenges for governments who seek to understand what kind of policy and regulation is appropriate. The GFN examines the rapidly developing science in relation to nicotine and its use, including policy and regulatory responses.
- Many different groups are involved in, or affected by, developments in safer nicotine products. These include:
- consumers, including people who have switched to these products or are thinking of doing so;
- academics and researchers, who are faced with new research questions about the safety and use of these products;
- parliamentarians and government officials, who need to consider what kind of regulation is appropriate;
- manufacturers, involved in developing and marketing new products; and
- public health experts, who need to advise populations about smoking, smoking cessation and safer nicotine products.
- consumers and consumer advocates;
- policy analysts;
- public health experts;
- parliamentarians and government officials;
- academics and researchers;
- product manufacturers and distributors; and
- media representatives.
The GFN started in 2014 with 200 delegates from 26 countries. By 2019, it had grown to 600 delegates representing 70 nations. All the conferences to date have been in Warsaw.
We aim to make the conference as accessible as possible. Our registration fees are offered on a sliding scale and start from as little as £135 for students, delegates from low and middle income countries, consumers and local participants.